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The use of exogenous surfactants has been introduced into the therapy of pa-
tients of different ages. Much better results have been obtained in the treat-
ment of respiratory distress syndrome with surfactants enriched with surfactant
proteins. In the following study we used protein-containing surfactants (survan-
ta and curosurf). The aim of the following study was to determine the localisa-
tion of artificial surfactants in the lung tissue. Using the Immunogold Technique,
biotinylated surfactant proteins were traced in the air-blood barriers. In all lungs
the exogenous surfactant was present only in some alveoli. In these parts small
areas of atelectasis as well as oedema and transudate accumulation were seen.
These changes were less severe after biotinylated curosurf treatment. In elec-
tron microscope studies we found surfactant elements in the air-blood barrier
and other structures of the alveolar septa. Immunogold studies confirm the pres-
ence of biotynylated surfactant in the elements of the air-blood barrier.
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INTRODUCTION
The first artificial surfactants were used in the
therapy of respiratory distress syndrome in neonates.
Now, they are also used in the prevention and treat-
ment of ARDS [2, 8]. Most data on the efficiency of
surfactants used in stabilisation at the air-fluid phase
are from in vitro studies [4]. An improvement in lung
aeration after surfactant instillation is well known.
However, side effects, such as pulmonary haemor-
rhages, brain haemorrhages, increased lung fibrosis
and even lung cavity formation with accompanied
infections, were also described [7]. The long-term
effects of surfactant therapy are still incomplete and
the results ambiguous [4, 7]. The question as to how
the exogenous surfactants can have any influence
on the development of alveoli or the remodelling of
mature ones remains an open one. Controlled in vivo
experiment with observation of the stages of injury,
regeneration and parenchymal rebuilding of the lung
has been incomplete. The aim of this study was the
tracing of exogenous surfactants within the air-blood
barrier structures in 24-hour observations.
MATERIAL AND METHODS
We used young adult pathogen-free rats of the
Wistar strain (body weight 240–250 g). After ana-
esthesia (narkotan) the animals were intubated and
a dose of surfactant (100 or 150 mg of lipids per kg
378
Folia Morphol., 2003, Vol. 62, No. 4
Figure 3. Anti-biotin-gold conjugated particles are found within
the vacuole, on cell surface, and beneath the epithelium on the
parts of surfactant. Immunogold. Primary magnification 20,000 ×.
Figure 1. Part of the thin air-blood barrier. Anti-biotin-gold conju-
gated particles are visible the epithelial cell membrane, in endot-
helial cytoplasm, and within capillary lumen. Immunogold. Prima-
ry magnification 12,000 ×.
Figure 2. Part of the alveolar septum. Anti-biotin-gold conjugated
particles are found on the cell surface and beneath the epithelium
on the parts of the surfactant. Immunogold. Primary magnifica-
tion 50,000 ×.
Figure 4. Anti-biotin-gold conjugated particles are found within
the lamellar body. Immunogold. Primary magnification 20,000 ×.
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of body weight; survanta and curosurf or biotiny-
lated curosurf respectively) was introduced directly
to the trachea. Controls were given an equivalent
volume of 0.9% NaCl. After 1, 3, 6, and 24 hours
the animals were sacrificed and the lungs removed
and processed in a routine procedure, the left lung
into paraffin blocks and the right into epon 812
blocks. There were not less then 7 and 4 animals
respectively in each of the studied groups and con-
trols. For the etching of resin for immuno-electron
microscopy we used a method with 3% sodium meta-
periodate described earlier [6] and then one-step
immuno-reaction was performed (goat anti-biotin
20 nm gold conjugated; ICN Biomedicals, Inc.).
RESULTS AND DISCUSSION
The exogenous surfactants introduced intratrache-
aly were distributed in the lungs only in a disperse
pattern. We were unable to record a uniform spread
of surfactants within the lung. In those parts where
the surfactant entered the alveoli, areas of athelecta-
sis as well as oedema and transudate accumulation
were observed. Erythrorrhagias were even observed
in some cases (24 hours, survanta and non-biotiny-
lated curosurf). Such changes were not observed in
controls. Surfactant structures were observed within
the structures of the thin air-blood barriers, alveolar
septa and within the capillary lumen (Fig. 1, 2). In
routine transmission electron microscopy inclusions
of surfactant particles into cell membrane systems was
observed. This was confirmed by Immunogold. Some
of the particles of biotinylated curosurf were found with-
in lamellar bodies of type II pneumocytes (Fig. 3, 4).
Respiratory distress syndrome in neonates and
adults has a high mortality rate [3, 9]. Although
clinical data describe the benefits of an acute phase
of the treatment, observations over a long period
are still incomplete [4]. Surfactants decrease the sur-
face tension (enabling gas exchange) and enhance
the transport of oedematous fluid into alveoli [1].
But the excess of surfactants could lead to some dam-
age of the cell membranes [10] and side effects in-
cluding haemorrhages [3]. Curosurf, containing neu-
tral lipids and specific proteins SP-B and SP-C, is the
surfactant preparation now used most widely in Eu-
rope. Experimental studies revealed that curosurf
forms a monolayer on the water surface very quickly
(“adsorption with click”) that is due to the high lip-
id concentration in a small volume. The ability to
form a monolayer is the key to its proper function.
But the vast majority of publications on this pro-
cess are based only on in vitro models and the re-
sults are confusing [4, 5]. This study confirms the
recycling of exogenous surfactants into lamellar
bodies. Moreover, biotinylated curosurf particles
were found in the monolayer of surfactant as well
as in the cell membrane systems. The clinical and
experimental studies conducted so far [9] have re-
vealed that in some cases lung fibrosis follows the
introduction of exogenous surfactants. The recycling
of exogenous surfactants may lead to increased
formation of lamellar bodies and their release and
then to increased macrophage stimulation. Accord-
ing to our previous data, surfactant recirculation
and an increase in the number of macrophages lad-
en with surfactant last for about 3 weeks [10]. The
concept that the surfactant-laden macrophages
contain the exogenous surfactant preparations for
so long requires further study.
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